464280.KQ
Tdspharm
KOE · Healthcare · Drug Manufacturers - General · KR
KRW 5,820.00
−1.02%Year over year
Reported trailing growth
- Revenue
- +43.4%
- EBITDA
- +86.4%
- EBIT
- +240.6%
- EPS
- +79.5%
- Free cash flow
- —
- Operating cash flow
- +280.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +2.6%
- EBITDA
- +3.4%
- EBIT
- -0.1%
- Net income
- +7.3%
- EPS
- -0.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026